



PROGRAM GUIDE

TEXAS HEALTHCARE AND BIOSCIENCE SUMMIT



CONNECTING THE DOTS: STRONG POLICIES FOSTER LIFE SAVING INNOVATIONS

The THBI Virtual Summit will highlight our organization's legislative priorities for the 87th Legislative Session.

THBI members are at the forefront of COVID-19 research and development; creating vaccines, therapeutics, and diagnostics to help cure, treat and prevent illness. Strong policies foster innovations necessary for our industry to end the pandemic and prevent future virus outbreaks and deadly diseases. The Summit will feature life science experts leading discussions on bringing a product(s) to the market, and how Texas' role and history of good policy is playing a part in bringing life-saving medications to patients.

JOIN THE CONVERSATION

SOCIAL MEDIA GUIDE



**Texas Healthcare and
Bioscience Institute**

**#THBISummit
#Innovation**



@TxHBI

**#txbioscience
#txlege**

TABLE OF CONTENTS

About THBI.....	4
THBI Board Members	5
Summit Program Schedule.....	6
Speaker, Panelist and Moderator Bios.....	8
Luminary Award Winners	21
Summit Sponsors	23



The Texas Healthcare & Bioscience Institute (THBI) is the leading voice of the Texas healthcare and bioscience industries. THBI is an advocacy organization focused on public policy in the life sciences and healthcare and bioscience industries. Our work extends beyond the Capitol as we partner with numerous economic development organizations across the state to recruit and retain jobs for Texas.

Our membership consists of biopharmaceutical companies, research institutions, medical device companies, economic development entities and service companies providing unparalleled networking and synergy to effectively address the public policy needs of Texas' growing life sciences community.

Become a THBI member to be a part of the important policy initiatives our industry will be working on during the 87th Legislative Session and THBI's 2021 programming schedule, including a series of member-only policy events. Contact info@thbi.com to learn more. Visit www.thbi.com to stay informed about upcoming events and opportunities.



THBI BOARD OF DIRECTORS

THANK YOU TO OUR BOARD MEMBERS FOR YOUR CONTINUED SUPPORT

CHAIRMAN

David R. Margrave
Lantern Pharma Inc.

VICE CHAIRMAN

Andrea Giuffrida, PhD
UT Health San Antonio

SECRETARY

Holly Jacques Turner
Merck

TREASURER

Bradley Westmoreland
Genentech, Inc.

PRESIDENT AND CEO

Tom Kowalski
Texas Healthcare and Bioscience Institute

Jeff Buel

Johnson & Johnson

Mark Moreno

*The University of Texas
MD Anderson Cancer Center*

Brynna Clark

PhRMA

Amber Pearce

Pfizer

Holli Hill

Novartis Pharmaceuticals

Joan Solem

Eli Lilly & Company

Kyle Kamrath

Vertex Pharmaceuticals

Jeffrey L. Wade

Lexicon Pharmaceuticals

SCHEDULE OF EVENTS

DECEMBER 9, 2020

1:00 pm	<p>OPENING CONVERSATION: A FIRESIDE CHAT</p> <ul style="list-style-type: none"> • Michelle McMurry-Heath, MD, PhD, President and CEO, BIO • Tom Kowalski, President and CEO, THBI
1:20 pm	<p>THBI'S LEGISLATIVE PRIORITIES FOR THE 87TH TEXAS LEGISLATIVE SESSION</p> <p>THBI is committed to creating an environment where innovation and discoveries flourish and thrive, and patients remain the ultimate beneficiary of such innovations. This panel will provide an overview of the priorities THBI members will be focused on during the 87th Texas Legislative Session.</p> <ul style="list-style-type: none"> • Holli Hill, State Government Affairs, Novartis • Amber Pearce, Director of US Public Affairs and State Government Relations, Pfizer • Meredith Armstrong, Policy Director, THBI • Moderator: Patricia Shipton, Government Affairs Consultant, THBI
2:00 pm	<p>KEYNOTE</p> <p>Understanding pharmaceutical cost and pricing issues in the U.S. health care system.</p> <ul style="list-style-type: none"> • Kipp Snider, National Vice President for State Policy, PhRMA
2:20 pm	<p>LIFE SCIENCES INDUSTRY UPDATES: PANEL 1</p> <p>The life sciences industry is leading the response to COVID-19 with more than 750 therapeutic developments in the pipeline. The importance of strong policies to support life science innovation is a leading issue on the agendas of policy makers. This panel brings together state and federal perspectives to provide insight on legislative initiatives impacting the country as we move from pandemic to a post-COVID environment; what health care issues will be prevalent as we move into a legislative season; and how can the biopharmaceutical industry continue to respond.</p> <ul style="list-style-type: none"> • State Senator Nathan Johnson, Texas State Senate, Member of Senate Health and Human Services Committee • Nick Magallanes, Vice President of Federal Advocacy, PhRMA • Patrick Plues, Vice President of State Government Affairs, BIO • Moderator: Jesse Lewis, Associate Director of State Government Affairs, Bristol Myers Squibb

2:50 pm	<p>LIFE SCIENCES INDUSTRY UPDATES: PANEL 2</p> <p>Texas is one of the leading life science states in the country with over 6,200 life science businesses employing over 100,000 employees. With academic research and development expenditures of nearly \$3.5 billion, nearly \$1.4 billion in NIH funding, 4,950 patent awards to Texas inventors, and \$2.3 billion in bioscience venture capital investments, Texas continues to outpace national growth for the industry. This panel will discuss the importance of academic and private partnerships, how initiatives that support research and development impact the Texas economy, and what policies are necessary to further strengthen the growth in the national and global competitive environment.</p> <ul style="list-style-type: none"> • State Representative Chris Turner, Texas House of Representatives, Chair of House Higher Education Committee • Claire Aldridge, PhD, Associate Vice President of Commercialization and Business Development, UT Southwestern • Fiona Mack, PhD, Head of JLABS @ TMC • Cindy WalkerPeach, PhD, Chief Product Development Officer, CPRIT • Moderator: Mark Moreno, Vice President of Government Relations, MD Anderson Cancer Center
3:40 pm	<p>KEYNOTE</p> <p>As the Chairman of the House Appropriations Committee, Representative Capriglione will share updates on the Legislative Budget Board, and his forecast on how the Appropriations Committee may prepare for the 2022-2023 budget with the current budget shortfalls.</p> <ul style="list-style-type: none"> • State Representative Gio Capriglione, Texas House of Representatives, Chair of House Appropriations Committee
4:00 pm	<p>LUMINARY AWARDS</p> <ul style="list-style-type: none"> • Governor Greg Abbott • Khrystal K. Davis, JD, Founder and President, Texas Rare Alliance <p>On behalf of health care workers:</p> <ul style="list-style-type: none"> • Texas U.S. Representative Michael Burgess, MD • Texas U.S. Representative Eddie Bernice Johnson • Texas State Senator Dawn Buckingham, MD • Texas State Senator Donna Campbell, MD • Texas State Senator Charles Schwertner, MD • Texas State Representative Greg Bonnen, MD • Texas State Representative Donna Howard • Texas State Representative Stephanie Klick • Texas State Representative Tom Oliverson, MD • Texas State Representative J.D. Sheffield, DO
4:15 pm	<p>POST-EVENT VIRTUAL RECEPTION</p> <p>Immediately following the Policy Summit, join special guest Rodney E. Rohde, PhD, MS, SV/SM/MB(ASCP)^{CM} and the THBI team, Tom Kowalski, Meredith Armstrong, and Patricia Shipton. The post-event virtual reception will be an open forum to ask questions about COVID-19 and what we can expect to see from the pandemic in 2021, answer questions on THBI's legislative priorities, and provide further insight into how policy makers can continue to support innovation and positive patient health outcomes during the upcoming legislative session.</p>

SPEAKERS, PANELISTS AND MODERATORS

IN ALPHABETICAL ORDER



CLAIRE ALDRIDGE, PhD


Associate Vice President, Commercialization and
Business Development
UT Southwestern Medical Center

Claire Aldridge, PhD serves as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center. She recently rejoined UT Southwestern after eight years with Remeditex Ventures, a local biotech venture fund. Dr. Aldridge brings more than 20 years' experience facilitating the translation of scientific discoveries into patient and commercial benefits.

Dr. Aldridge has leveraged her training as a translator, or liaison, between scientists and non- scientists, communicating effectively about the potential of science. Her roles have included technology commercialization; improving patient outcomes through quality based initiatives; working with disease-specific nonprofits; development and venture philanthropy; and biotech and life science investing through venture capital.

In addition to broadening the pipeline of commercialization opportunities for UT Southwestern discoveries, she plans to bring her science communication, commercialization and venture capital skills together with other science and civic leaders to grow and more deeply establish a biotech ecosystem in the North Texas region.

Dr. Aldridge received her PhD from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.



MEREDITH ARMSTRONG

Policy Director
Texas Healthcare and Bioscience Institute (THBI)

Meredith Armstrong serves as the Policy Director for the Texas Healthcare and Bioscience Institute, where she collaborates and establishes the strategic direction for THBI. Meredith began her legislative career in the Texas House as an intern in 2010. She returned in 2016 to work as the Legislative Director to former Texas State Representative John M. Zerwas, M.D. Meredith was an Account Director at an association management company and a Marketing Coordinator for Memorial Hermann Hospital - Texas Medical Center during the time between her tenures at the Texas Legislature.

Meredith holds a Bachelor of Science degree in Communication Studies from The University of Texas at Austin.




GIOVANNI CAPRIGLIONE

State Representative
Chair of House Appropriations Committee
Texas House of Representatives

Giovanni has been married to his wife Elisa for 19 years, and has three children attending Carroll ISD schools. After receiving his BS in Physics, he pursued his MBA in Finance from Santa Clara University. After school, Giovanni went on to work for a DFW based venture capital/private equity firm.

Giovanni is now the owner and president of his own small business, Texas Adventure Capital LLC, which provides business services to various investment fund managers and business owners. His focus is investing in Texas-based small businesses. Previously, Giovanni held various positions at computer engineering companies specializing in semiconductor design and Internet products, and was senior vice president at an investment firm where he managed the loan and equity portfolios of various American businesses.

Giovanni was elected to the Texas House of Representatives in 2012 and is serving his fourth term representing District 98 which encompasses all or part of Grapevine, Colleyville, Southlake, Keller, Westlake, North Fort Worth, and Haslet. He currently serves as the chairman of the House Committee on Appropriations, is a member of the Select Committee on Mass Violence Prevention & Community Safety, and co-chair of the Texas Privacy Protection Advisory Council. He is a member of the following House caucuses: Innovation & Technology Caucus, Manufacturers Caucus, Rural Caucus, Sportsman's Caucus, Veteran's Caucus, Farm to Table Caucus, and the Fine Arts Education Caucus. Giovanni also chairs the Tarrant County Delegation.



HOLLI HILL

Director of State Public Affairs
Novartis Pharmaceuticals

Holli Hill is the Director of State Public Affairs at Novartis where she covers a 5 state region, including Texas. She has over 15 years of experience in the pharmaceutical industry, working on both brand name and generic drug issues including Co-Chairing a national coalition on increasing access to biosimilar products. Holli is a graduate of The University of Texas at Austin and a native of Austin, Texas.




NATHAN JOHNSON

State Senator
Member of Senate Health and Human Services
Committee
Texas State Senate

Elected with strong bipartisan support in 2018, Senator Nathan Johnson represents the economically and demographically diverse Senate District 16, which comprises the northern part of Dallas County.

Johnson graduated magna cum laude with a degree in physics from the University of Arizona, and earned his law degree from The University of Texas at Austin. He practices law in the Trial Practice Group at the law firm of Thompson & Knight. He has also composed music for the classical concert stage and scored the hit television series Dragon Ball Z.

Johnson passed 22 bills into law during his first legislative session, all with bipartisan support. He earned a reputation for being a quick study who convenes and considers the views of diverse constituencies, and pursues creative public policy solutions. His emphasis on improving the health of Texans prompted him to author and support a number of healthcare initiatives, ranging from medical coding to Medicaid expansion, with much in between. Heading into next session, Johnson and his team are developing legislative strategies to foster sustainable, economic growth and broaden opportunity.



TOM KOWALSKI

President and CEO

Texas Healthcare and Bioscience Institute (THBI)

Tom Kowalski is President and CEO of the Texas Healthcare and Bioscience Institute (THBI) in Austin, Texas.

He has previously served as a senior staff member to Governor Bill Clements of Texas, U.S. Senator John Tower of Texas, and Congressman Jim Collins of Dallas, Texas.

With over thirty-five years of political and policy experience, Mr. Kowalski was appointed in 1989 by Governor Bill Clements to the Board of Regents of the Texas State University System. He served as Chairman of the Board of Regents in 1995. In addition, Mr. Kowalski currently serves as Chairman of the McCoy College of Business Administration Advisory Council at Texas State University.

An avid public speaker, Mr. Kowalski gives numerous talks on positioning Texas as a global leader in the development of biotechnology and life sciences. He was appointed in 2002 to Governor Rick Perry's State Council on Science and Biotechnology Development. He is the former Chairman of Bio's Council of State Biotechnology Associations, whose national membership consists of forty-nine state associations involved in biotechnology development and advocacy. Mr. Kowalski is a distinguished alumni of Texas State University.

A lifelong Texan, Mr. Kowalski resides in Austin, Texas with his wife, Susie.



JESSE LEWIS

Associate Director of State Government Affairs

Bristol Myers Squibb

Jesse Lewis is Associate Director of State Government Affairs for Bristol Myers Squibb (BMS), overseeing a five state territory which includes Texas, Louisiana, Arkansas, Mississippi, and Kansas. In this role, he develops

key relationships with policy makers and stakeholders in order to promote legislative and regulatory policies that enable appropriate patient access to life saving therapies.

Jesse has over 22 years of experience in government affairs both inside and outside of Texas state government. Before joining BMS in 2012, Jesse served as Executive Director of the Republican Party of Texas (RPT). In that role, he oversaw the business operations and political strategy for the RPT. Prior to that, Jesse served as the Director of External Relations for the Texas Workforce Commission, where he managed the Commission's government relations, communications, customer relations, media and conference planning activities, and labor market information programs. Jesse began his government affairs career serving as Chief of Staff to former Texas Representative Arlene Wohlgenuth. Jesse lives in Dripping Springs, Texas with his two children.



FIONA MACK, PhD

Head of JLABS @ TMC

As Head of JLABS @ TMC, Fiona is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. In this role, she catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, consumer, and healthtech sectors.

Prior to joining JLABS, Fiona was Senior Director of External Innovation at Ipsen, supporting the expansion of the Rare Disease and Neuroscience portfolios. Before joining Ipsen, Fiona was a Director of External Innovation Oncology Discovery at Roche. While at Roche, she led cross-functional teams to identify and evaluate opportunities based on their scientific merit and strategic alignment with oncology/immuno-oncology early discovery and clinical development pipelines. Notable activities include the acquisition of Tensha Therapeutics, Tusk Therapeutics and Ignyta, in addition to early discovery academic collaborations.

Fiona began her career in industry as a Senior Research Scientist at Wyeth Oncology and eventually took on a senior leadership role when the company was acquired by Pfizer. Fiona was able to complement internal early drug discovery expertise with external innovation as a program leader for pipeline projects. She also led external collaborations to support IND-enabling studies for anti-sense therapeutics, bi-specific immunotherapies and antibody drug conjugates.

Fiona earned her PhD in Cell and Molecular Biology from the University of Pennsylvania and her undergraduate degree in Biology from Cornell University. Her innovative work has been published in high impact journals and she also has several granted patents.



MICHELLE MCMURRY-HEATH, MD, PhD

President and CEO

Biotechnology Innovation Organization (BIO)

Michelle McMurry-Heath assumed the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO on June 1, 2020. A medical doctor and molecular immunologist by training, Dr. McMurry-Heath becomes

just the third chief executive to steward the world's largest biotechnology advocacy group since BIO's founding in 1993.

BIO represents 1,000 life sciences companies and organizations from 30 countries. The organization's mission is to support companies that discover and deploy scientific breakthroughs that improve human health, environmental stewardship, and sustainable agriculture.


The common thread in McMurry-Heath's work across academia, government and industry has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, McMurry-Heath calls "the distribution of scientific progress the social justice issue of our age."

She comes to BIO from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. She was also instrumental in bringing J&J's incubator, J Labs, to Washington, DC. She led a global team of 900 with responsibilities in 150 countries around the globe.

Prior to her time at J&J, Dr. McMurry-Heath was also a key science policy leader in government. The Obama-Biden transition team tapped her to conduct a comprehensive analysis of the National Science Foundation's policies, programs and personnel. President Obama then named her associate science director of the FDA's Center for Devices and Radiological Health under Commissioner Peggy Hamburg. In that role, she championed clinical trial evolution, the use of real-world evidence in product evaluation, and an embrace of the patient's voice in health research so new medical products deliver outcomes that matter to them.

McMurry-Heath was the founding director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program, where she promoted personalized medicine and bolstered international preparation for pandemic disease threats. She received her early training in science policy from the Robert Wood Johnson Foundation and later served as Senator Joe Lieberman's top legislative aide for science and health. In that role, she drafted legislation to protect the country from biological attacks.

McMurry-Heath received her MD/PhD from Duke's Medical Scientist Training Program, becoming the first African-American to graduate from the prestigious program. She spent 12 years working at the research bench before taking policy and leadership roles in government and industry.



NICK MAGALLANES

Vice President of Federal Affairs
Pharmaceutical Research and Manufacturers of
America (PhRMA)

Nick Magallanes currently serves as Vice President of Federal Affairs at PhRMA. He is responsible for PhRMA's advocacy in the U.S. Senate, with senior Republicans in Congress, and for several aspects of PhRMA's political advocacy program. Prior to joining PhRMA, Mr. Magallanes was a Director of Federal Relations at BIO. Nick kicked off his career in Washington working on Capitol Hill, first in the Senate for U.S. Senator Lamar Alexander (R-TN), and then in the House of Representatives for Rep. Lee Terry and the Energy and Commerce Committee, and the House Republican Conference. While at the Conference, he served as Senior Policy Advisor responsible for domestic policy issues. Mr. Magallanes holds a B.A. in Economics and History from Vanderbilt University, an M.S. in Health Policy from George Mason University, and a J.D. from the Columbus School of Law at the Catholic University of America. He resides in Alexandria, VA with his wife, son, and yellow lab Fitzwallace.



MARK MORENO

Vice President for Governmental Relations
The University of Texas MD Anderson Cancer
Center

Mark Moreno is the Vice President for Governmental Relations at The University of Texas MD Anderson Cancer Center. In this role, he advises the President on legislative and regulatory issues affecting MD Anderson at all levels of government and makes recommendations about courses of action that are in the best interest of the institution and its patients. His office is responsible for developing MD Anderson's federal and state budget and policy priorities for Congress and the Texas legislature.

Mr. Moreno also co-directs the Cancer Moon Shots Program Cancer Prevention and Control Platform, a cross functional team of experts focused on activities in the domains of policy, education (public and professional) and community-based clinical services (PES) aimed at significantly reducing the cancer burden in the community through implementation and dissemination of evidence-based interventions. The platform partners with international, national, state and local-level organizations to develop, implement and disseminate initiatives of common interest.

He has served the MD Anderson Office of Governmental Relations for more than 25 years, joining the institution after working more than 7 years as a legislative and budget aide in the Texas legislature, earning experience in the House and Senate on health and human services and higher education budget and policy issues. Between 2004 and 2006, he also managed governmental relations for The University of Texas Medical Branch at Galveston.

Mr. Moreno received a Bachelor of Arts degree in government from The University of Texas at Austin. He is married and has two children.



AMBER PEARCE

Director of US Public Affairs and State
Government Relations
Pfizer

Amber Pearce is currently the Director of US Public Affairs and State Government Relations for Pfizer Inc. covering Texas, Oklahoma, and New Mexico. She began

her career serving at the Texas State Capitol as a legislative staff member, despite working a brief stint as a children's ski instructor in Winter Park, Colorado. Amber worked for the Texas Healthcare and Bioscience Institute as their VP of Policy prior to joining Pfizer Inc. in 2010.

Amber currently serves on multiple work-related boards holding officer positions at both the Texas Association of Manufacturers and the Pharmaceutical Research and Manufacturers Association Task Force in Texas. She is also a Board Member of the Wine and Food Foundation of Texas.

An active enthusiast involved in skiing running, water sports and sand volleyball, she spends much of her spare time traveling to new spots around the world and US in search of the best sunset photo, glass of wine, and grilled octopus. Ms. Pearce graduated from Texas A&M University, is an animal lover and dog mom to a rescue Boxer mix, and originally hails from Georgetown, Texas, just a few miles north of Austin.



PATRICK J. PLUES

**Vice President, State Government Affairs
Biotechnology Innovation Organization (BIO)**

Patrick Plues has been involved with the biopharmaceutical industry for over 20 years and spans the breadth of the industry. He has worked in large fortune 100 biopharmaceutical companies to mid-sized specialty product companies and in industry trade organization.

Patrick started his career in the early 1990s working on Capitol Hill for United States Representative Robert Wise, a Democrat from West Virginia.

Patrick left Washington, DC in 1998 and moved to Philadelphia where he joined Wyeth Pharmaceuticals. He spent eleven years working in public affairs focused on state and federal legislative initiatives in women's health, childhood and adult immunization, and new breakthrough biologic therapies. While at Wyeth, Patrick worked extensively with external third-party stakeholders including patient advocacy organizations, consumer groups and public policy think tanks. He also successfully managed Wyeth's political action committee and employee grassroots program.

After Wyeth, Patrick became Director of Federal Government Affairs at Cephalon Inc., a specialty biopharmaceutical company headquartered outside of Philadelphia. In that role, he represented Cephalon's interest during Congressional consideration of the Affordable Care Act. Patrick also managed federal health policy and reimbursement and third-party alliance development efforts at Cephalon.

In 2014, he joined the Biotechnology Innovation Organization (BIO) as Vice President for State Government Affairs. Patrick has responsibility for all state-level legislative advocacy efforts for BIO, which includes work in both healthcare and ag-biotech.

Patrick is a native of Irwin, Pennsylvania, which is in the Pittsburgh metropolitan area. He now resides north of Philadelphia in Bucks County, Pennsylvania. Patrick is a 1991 graduate of West Virginia University in Morgantown, WV.



**RODNEY E. ROHDE, PhD, MS, SV/SM/
MB(ASCP)_{CM}**

Chair, Clinical Laboratory Science (CLS) Program
College of Health Professions
Texas State University

Rodney E. Rohde, PhD is a Professor and Chair for the Clinical Laboratory Science (CLS) Program in the College of Health Professions at Texas State University. He is Associate Director for the Translational Health Research Center. Dr. Rohde is a Global Fellow, Fellow of the Association of Clinical Scientists, and Honorary Professor of International studies. He is an ASCP board certified Specialist in Virology, Microbiology and Molecular Biology.

He spent a decade as a public health microbiologist and molecular epidemiologist with the Texas Department of State Health Services (DSHS) Bureau of Laboratories and Zoonosis Control Division prior to his academic career, including two terms as a CDC Visiting Scientist. Dr. Rohde served as Associate Dean for Research in the College of Health Professions for nine years. His research interests include Healthcare Associated Infections (HAIs), antimicrobial resistance, and clinical/public health microbiology especially zoonotic diseases (Rabies, Hantavirus, and others).

Dr. Rohde has published over 75 research articles and abstracts, two books, and is a highly sought keynote presenter with over 100 international, national, and state conference presentations. In recent years, he has become a globally viral author subject matter expert utilizing invited articles, TEDx talks, podcasts, video casts and interviews to enhance science communication and translational health research literacy in public health, healthcare and the medical laboratory environment. During the #SARSCoV2/#COVID19 pandemic, Doc R is the #1 quoted Texas State subject matter expert and has conducted over 110 interviews for podcasts, TV, newspapers, and internet sites as well as delivered dozens of webinars and workshops at the international, national, state, and local levels. He has received numerous awards and honors during his career, most recently he was named to The Pathologist's PowerList 2020 (global award).



PATRICIA SHIPTON


**Government Affairs Consultant
Texas Healthcare and Bioscience Institute (THBI)**

Patricia Shipton is a veteran of the Texas Legislature, having served for decades in both the public and private sectors. She has worked for Speaker Joe Straus since 2012, serving first as Strategic Legislative Advisor before being promoted to Chief of Staff in 2015.

In her role as the chief of staff, Ms. Shipton has worked closely with both the Governor's Office and the Lieutenant Governor's Office, as well as various caucuses and interest groups to collaborate on solutions for vital issues facing the state. During her time as the strategic legislative advisor, she guided important legislation through the House addressing water issues, mental health reforms, human trafficking, border security, public school finance, as well as three balanced biennial state budgets.

Ms. Shipton was a member of Governor Rick Perry's senior staff from January 2001 to September 2004. She became the first woman and first Hispanic to hold the post of Director of Legislative Affairs in the governor's office, where she was the liaison to the Texas Senate, Texas House of Representatives, the Lt. Governor's Office, and the Speaker's Office. Her leadership and strong working relationships with legislators and staff helped secure passage of many of the governor's legislative priorities, including the Trans-Texas Corridor, the Texas Grants II Program, and a border telemedicine project. Ms. Shipton also worked in the private sector as a governmental affairs consultant both before and after joining Governor Perry's staff.

A native of Laredo, Texas, Ms. Shipton is a graduate of The University of Texas at Austin, where she earned a BA in English and Psychology.



KIPP SNIDER

**National Vice President for State Policy
Pharmaceutical Research and Manufacturers of
America (PhRMA)**

Kipp Snider is National Vice President, State Policy at PhRMA. In this role, he leads PhRMA's field-based policy team in the state capitals. Prior to joining PhRMA, Kipp spent nearly 13 years at Amgen, where he helped establish and develop the company's state lobbying team. He has extensive experience in a wide variety of key policy issues affecting the biopharmaceutical industry, including Medicaid reimbursement, patient access, pricing, biosimilars, and drug disposal.

Before joining Amgen, Kipp worked in State Government Affairs for Pharmacia Corporation. He began his career as a commercial litigator at Howrey & Simon, a Washington, DC law firm. Kipp received his J.D. from George Washington University and his undergraduate degree from the College of William & Mary. He lives in Arlington, Virginia with his wife, Brenna, and their three children.



CHRIS TURNER

State Representative
Chair of House Higher Education Committee
Texas House of Representatives

In 2020, State Representative Chris Turner was elected to his sixth term in the Texas Legislature where he represents major portions of Arlington and Grand Prairie

in Tarrant County.

Among his many accomplishments in office, Chris has championed transformative legislation and efforts that directly impact his community. Chris created the Veterans Cash scratch-off ticket that has raised over \$150 million to aid veterans and their families. Chris brokered the deal to end the stalemate on Texas' major school finance legislation by crafting a statewide teacher pay raise plan that was supported by the House and Senate. He was instrumental in Arlington and Grand Prairie passing payday lending ordinances that protect vulnerable Texans. He has authored laws that safeguard consumers from unexpected utility rate hikes and tenants from unscrupulous landlords.

In January 2019, Chris was appointed to serve as Chair of the House Committee on Higher Education. In this role, he improved the transferability of college credits, protected students from perpetrators of sexual assault and other serious misconduct, and lowered the cost of college education by expanding access to open educational resources.

Chris is Vice Chair of the House Committee on Redistricting and a member of the House Committee on Insurance. In January, Chris was elected to serve his 2nd term as Chair of the House Democratic Caucus where he leads 67 members with a comprehensive strategic approach to maximize the Caucus' political power in order to advance better public policy.

A lifelong Texan and Dallas native, Chris is a graduate of The University of Texas at Austin. Chris and his wife, Lisa, reside in Grand Prairie with their rescue dogs, Cassie, Cora and Cleo.



CINDY R. WALKERPEACH, PhD

Chief Product Development Officer
Cancer Prevention & Research Institute of Texas
(CPRIT)

Dr. WalkerPeach returned to Central Texas to lead CPRIT's Product Development Program which critically evaluates and invests in Texas-based companies with promising novel cancer-focused products (drugs, diagnostics, medical devices and other non-traditional oncology applications) and services that will benefit cancer patients and society.

Prior to joining CPRIT, she served as Program Director for the National Science Foundation (NSF) Innovation Corps (I-Corps) program in Washington, DC. NSF I-Corps prepared research scientists to extend their focus beyond the university laboratory and accelerated the economic and societal benefits of research projects with commercialization potential. She joined NSF from The University of Texas at Austin where she was a Director at the Austin Technology Incubator, having served as lead advisor for healthcare-focused life sciences startups. She was responsible for evaluating new business ventures, managing a portfolio of bioscience startups and providing business mentoring to technology-focused faculty and entrepreneurs.

Prior to government service, Dr. WalkerPeach had more than 20 years of experience in the biotechnology sector as a member of several life science company management teams. Dr. WalkerPeach completed a BS in Chemistry and holds a PhD in Molecular Biology.



CONGRATULATIONS TO OUR LUMINARY AWARD WINNERS

The Luminary Award is presented to individuals for their contributions and efforts to further the development of the life science industry in Texas. THBI honors elected officials, patient advocates, researchers, and industry leaders.

TEXAS GOVERNOR GREG ABBOTT

For his dedication to furthering the life science industry in Texas
and his response to coronavirus.

KHRYSTAL DAVIS, JD

Founder and President of Texas Rare Alliance


For her advocacy and dedication to patients with rare diseases and
her efforts to improve access to life saving medications.

TEXAS HEALTH CARE WORKERS ON THE FRONT LINES RESPONDING TO CORONAVIRUS

On behalf of health care workers:

Texas U.S. Representative Michael Burgess, MD
Texas U.S. Representative Eddie Bernice Johnson
Texas State Senator Dawn Buckingham, MD
Texas State Senator Donna Campbell, MD
Texas State Senator Charles Schwertner, MD
Texas State Representative Greg Bonnen, MD
Texas State Representative Donna Howard
Texas State Representative Stephanie Klick
Texas State Representative Tom Oliverson, MD
Texas State Representative J.D. Sheffield, DO

Thank you to our Texas elected officials and Texas Health Care Workers on the Front Lines responding to the coronavirus. These selfless people have been thrust into critical roles during the pandemic to care for patients while risking their own health.



**SCIENCE WILL BRING US
BACK TO NORMAL.**



See the progress at PhRMA.org/coronavirus

PhRMA
RESEARCH • PROGRESS • HOPE

THANK YOU SUMMIT SPONSORS

PRESENTING SPONSOR



**Complete list at time of publishing*



BIOTECHNOLOGY INNOVATION INDUSTRY (BIO)

bio.org

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

Contact

Brittany Calderon
bcalderon@bio.org

Social

[Twitter](#)



MERCK
INVENTING FOR LIFE

[MERCK](http://merck.com)
merck.com

Merck aspires to be the premier research-intensive biopharmaceutical company in the world

For more than 125 years, Merck (known as MSD outside of the U.S. and Canada) has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives.

We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.

Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.

Contact

Holly Turner
holly.turner@merck.com



TEXAS HEALTHCARE AND BIOSCIENCE SUMMIT

THANK YOU FOR JOINING US!

 facebook.com/txhbi

 [@TXHBI](https://twitter.com/TXHBI)

#THBISummit



WWW.THBI.COM

(512) 708-8424

807 BRAZOS STREET, SUITE 607
AUSTIN, TX 78701

